GlassScriptPhysician profile
William C Owen
NPI 1306885876
$68,205.30
in general payments reported to CMS, 2019-2025
17 companies · $770 in 2025
The $770 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $21K · 2021: $8,553 · 2022: $9,830 · 2023: $8,028 · 2024: $286 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,015 · Food and Beverage: $1,546 · Travel and Lodging: $1,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,015.00 |
| Food and Beverage | $1,546.44 |
| Travel and Lodging | $1,522.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $38,444.47 | 2019-2020 | |
| Global Blood Therapeutics, INC. | $19,919.40 | 2020-2022 | |
| Pfizer INC. | $8,084.55 | 2023-2024 | |
| Agios Pharmaceuticals, INC. | $294.55 | 2019-2025 | Pyrukynd |
| Novo Nordisk INC | $246.39 | 2025 | |
| Genzyme Corporation | $201.63 | 2020-2022 | |
| Sobi, INC | $189.97 | 2019-2025 | |
| Genetix Biotherapeutics INC | $162.28 | 2025 | Lyfgenia |
| Servier Pharmaceuticals LLC | $157.81 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $126.49 | 2022 | |
| Amgen INC. | $120.60 | 2023 | Blincyto |
| Qol Medical, LLC | $90.10 | 2024 | Sucraid |
| Genentech USA, INC. | $65.71 | 2019-2021 | |
| Adaptive Biotechnologies Corporation | $64.30 | 2022 | |
| Rare Disease Therapeutics, INC. | $24.08 | 2025 | Xromi |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $12.97 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Owen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.